UNLIMITED TURBO LONG - AMGEN | Delayed Deutsche Boerse AG 10:50:56 18/06/2024 pm IST | ||
| 15.94 EUR | +0.82% |
|
| 1 month | -4.18% | ||
| 3 months | +25.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 15.94 | +0.82% |
| 17/24/17 | 15.81 | +3.00% |
| 14/24/14 | 15.35 | -0.07% |
| 13/24/13 | 15.36 | -0.45% |
| 12/24/12 | 15.43 | -0.77% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 10:50 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
BNP Paribas
|
| WKN | PZ61RF |
| ISIN | DE000PZ61RF5 |
| Date issued | 08/03/2019 |
| Strike | 135.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.28 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.14 € |
|---|---|
| Lowest since issue | 3.77 € |
| Spread | 0.01 € |
| Spread % | 0.06% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
303.3
USD
Average target price
316.4
USD
Spread / Average Target
+4.34%
- Stock Market
- Certificates
- Certificat
